Event

Evolve to Excellence (2013)

Purdue’s 2013 sales program, built with McKinsey, aimed at high-volume OxyContin prescribers.

7 links, 7 backed by primary records

Connections 7

Purdue Pharma ran the program Primary record 1
McKinsey & Company advised Purdue on it; the 2024 agreed statement of facts says the advice included how to "turbocharge" OxyContin’s sales pipeline Primary record 1
Richard Sackler named in the 2020 Justice Department settlement as having approved it (an allegation; no determination of liability) According to U.S. Department of Justice Primary record 2
Kathe Sackler named in the 2020 Justice Department settlement as having approved it (an allegation; no determination of liability) According to U.S. Department of Justice Primary record 2
David Sackler named in the 2020 Justice Department settlement as having approved it (an allegation; no determination of liability) According to U.S. Department of Justice Primary record 2
Mortimer D. A. Sackler named in the 2020 Justice Department settlement as having approved it (an allegation; no determination of liability) According to U.S. Department of Justice Primary record 2
Jonathan Sackler named in the 2020 Justice Department settlement as having approved it (an allegation; no determination of liability) According to U.S. Department of Justice Primary record 2

Timeline 1 date

Proof 2 sources

Justice Department Announces Resolution of Criminal and Civil Investigations into McKinsey & Company’s Work with Purdue Pharma L.P.; Former McKinsey Senior Partner Charged with Obstruction of Justice, U.S. Attorney’s Office, Western District of Virginia, 13 Dec 2024. Primary record Archived copy
In May 2013, Purdue retained McKinsey to conduct a rapid assessment of the underlying drivers of OxyContin performance
This 2013 effort was called Evolve to Excellence, or “E2E,” and included McKinsey advising Purdue on how to “turbocharge” the sales pipeline for OxyContin by, among other strategies, intensifying marketing to High Value Prescribers
Justice Department Announces Global Resolution of Criminal and Civil Investigations with Opioid Manufacturer Purdue Pharma and Civil Settlement with Members of the Sackler Family, U.S. Department of Justice, 21 Oct 2020. Primary record Archived copy
The Named Sacklers then approved a new marketing program beginning in 2013 called “Evolve to Excellence,” through which Purdue sales representatives intensified their marketing of OxyContin to extreme, high-volume prescribers

Page history 1 change